Ophthalmology

IVERIC bio

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

IVERIC bio Announces First Patient Dosed in Second Zimura® Phase 3 Clinical Trial

Lead Product(s): Avacincaptad Pegol

Therapeutic Area: Ophthalmology Product Name: Zimura

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 30, 2020

Details:

First patient has been dosed in GATHER2, also known as ISEE2008, the second Phase 3 clinical trial for Zimura® (avacincaptad pegol), a novel complement C5 inhibitor, in development for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

Eyenovia

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Eyenovia Resumes Recruitment of Phase III CHAPERONE Study for Progressive Myopia

Lead Product(s): Atropine

Therapeutic Area: Ophthalmology Product Name: MicroPine

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 30, 2020

Details:

The study is investigating the safety and efficacy of MicroPine for the reduction of progressive myopia using Eyenovia’s proprietary atropine topical micro-formulation delivered by the Optejet™ dispenser.

Samsung Bioepis

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Samsung Bioepis Begins Phase 3 Trial for Aflibercept Biosimilar

Lead Product(s): Aflibercept

Therapeutic Area: Ophthalmology Product Name: SB15

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 30, 2020

Details:

The randomized, double-masked, parallel group, multicenter study will compare SB15 and reference Eylea on safety, efficacy, pharmacokinetics, and immunogenicity.

AsclepiX Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

AsclepiX Therapeutics Announces $35 Million Series A Financing

Lead Product(s): AXT107

Therapeutic Area: Ophthalmology Product Name: AXT107

Highest Development Status: Preclinical Product Type: Peptide

Partner/Sponsor/Collaborator: Perceptive Xontogeny Venture Fund

Deal Size: Undisclosed Upfront Cash: $35.0 million

Deal Type: Series A Financing June 24, 2020

Details:

Proceeds will be used to fund development of AXT107 for treatment of retinal diseases through Phase 1/2a clinical trials.

Aerpio Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Aerpio Announces Initiation of 28-Day Phase 2 Razuprotafib Glaucoma Trial

Lead Product(s): Razuprotafib

Therapeutic Area: Ophthalmology Product Name: AKB-9778

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 24, 2020

Details:

Aerpio Pharmaceuticals has commenced patient enrollment in its double-blind, placebo-controlled Phase 2 trial in patients with elevated intraocular pressure (IOP) associated with open angle glaucoma (OAG) or ocular hypertension (OHT).

Tarsius Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Tarsius Pharma Completes Patient Enrollment in Clinical Trial of TRS01 in Patients With Non-infectious Uveitis

Lead Product(s): TRS01

Therapeutic Area: Ophthalmology Product Name: TRS01

Highest Development Status: Phase I/ Phase II Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 22, 2020

Details:

TRS01 is a Potential topical immune-modulator agent with a novel mechanism of action for treatment of ocular inflammation. This phase I/II trial is a dose ranging trial to evaluate the safety and efficacy of TRS01 in patients with anterior non-infectious active uveitis.

Aurinia Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Aurinia Completes Patient Enrollment Into the AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution

Lead Product(s): Voclosporin

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Phase II/ Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 22, 2020

Details:

Aurinia has completed enrollment for the Phase 2/3 AUDREY™ clinical trial evaluating voclosporin ophthalmic solution (VOS) for the potential treatment of dry eye syndrome (DES), a chronic disease estimated to affect more than 16 million people in the United States.

Ocuphire Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Rexahn and Ocuphire Enter into Definitive Merger Agreement

Lead Product(s): Phentolamine

Therapeutic Area: Ophthalmology Product Name: Nyxol

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Rexahn Pharmaceuticals Inc

Deal Size: $21.1 million Upfront Cash: Undisclosed

Deal Type: Merger June 18, 2020

Details:

This merger supports Ocuphire for advancement of its late-clinical stage small molecule ophthalmic pipeline including its Nyxol® Eye Drops, a once-daily eye drop formulation of phentolamine mesylate designed to reduce pupil diameter and improve visual acuity.

Lineage Cell Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Lineage Cell Therapeutics Reinitiates Patient Enrollment in Clinical Study of OpRegen® for the Treatment of Dry AMD With Geographic Atrophy

Lead Product(s): Retinal pigment epithelial cells

Therapeutic Area: Ophthalmology Product Name: OpRegen

Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 18, 2020

Details:

The company has restarted patient enrollment in a Phase 1/2a study of OpRegen a retinal pigment epithelium cell transplant therapy currently in development for the treatment of dry age-related macular degeneration.

NTC S.r.l.

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ITALY Italy

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

NTC Grants License and Distribution Rights in Israel to Taro Pharmaceutical Industries

Lead Product(s): Levofloxacin,Dexamethasone

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Taro Pharmaceutical Industries Ltd.

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement June 17, 2020

Details:

NTC Srl has granted exclusive license and distribution rights to one of its R&D products to Taro Pharmaceutical. The product combines a quinolone antibiotic with an anti-inflammatory steroid in eye drops intended to provide an appropriate treatment for post-cataract surgery.

Find

Find Ophthalmology Clinical Drug Pipeline Developments & Deals

Product Type

Development Status

IVERIC bio

IVERIC bio Announces First Patient Dosed in Second Zimura® Phase 3 Clinical Trial

Eyenovia

Eyenovia Resumes Recruitment of Phase III CHAPERONE Study for Progressive Myopia

Samsung Bioepis

Samsung Bioepis Begins Phase 3 Trial for Aflibercept Biosimilar

AsclepiX Therapeutics

AsclepiX Therapeutics Announces $35 Million Series A Financing

Aerpio Pharmaceuticals

Aerpio Announces Initiation of 28-Day Phase 2 Razuprotafib Glaucoma Trial

Tarsius Pharma

Tarsius Pharma Completes Patient Enrollment in Clinical Trial of TRS01 in Patients With Non-infectious Uveitis

Aurinia Pharmaceuticals

Aurinia Completes Patient Enrollment Into the AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution

Ocuphire Pharma

Rexahn and Ocuphire Enter into Definitive Merger Agreement

Lineage Cell Therapeutics

Lineage Cell Therapeutics Reinitiates Patient Enrollment in Clinical Study of OpRegen® for the Treatment of Dry AMD With Geographic Atrophy

NTC S.r.l.

NTC Grants License and Distribution Rights in Israel to Taro Pharmaceutical Industries